Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01390818 · MORE INFO

Limitations, agreements, and source contact

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors · Source last updated 2017-03-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
service@merckgroup.com
organization
Merck Serono, a business of Merck KGaA, Darmstadt, Germany
phone
+496151725200
title
Merck KGaA Communication Center
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
service@merckgroup.com
organization
Merck Serono, a business of Merck KGaA, Darmstadt, Germany
phone
+496151725200
title
Merck KGaA Communication Center

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice